Project Details
Description
DESCRIPTION: (Adapted from Applicant's Abstract) Human cytomegalovirus (HCMV),
a herpesvirus, is a major opportunistic infectious agent in individuals
suffering from AIDS, as well as individuals with suppressed immune systems (for
example, organ and bone marrow transplant recipients). Both primary and
reactivated latent HCMV infections can cause severe acute diseases in these
individuals, such as retinitis, pneumonitis, hepatitis and gastroenteritis.
Current therapies against HCMV infections are mostly targeted at the DNA
polymerase of the virus, and are limited in their usefulness by their toxic
side effects. In addition, viral resistance to anti-herpes agents is becoming
an increasingly more significant problem. Therefore, new and efficacious
treatments for HCMV infections, and herpesvirus infections in general, are
highly desirable. The protease of herpesviruses is essential for their life
cycle, and represents a novel target for the design and development of
anti-herpes chemotherapeutic agents. Several classes of inhibitors against HCMV
protease have been reported, but none of these have sufficient potency and/or
pharmacokinetic properties. Breakthroughs are needed to develop a new
generation of inhibitors against the protease, with higher potency, metabolic
stability, and oral bioavailability. Structure-based drug design can play an
important role in this process, as it has in the development of AIDS
therapeutic agents targeted at the HIV protease. Such design efforts require a
detailed structural and biochemical knowledge of the protein target, which are
currently still lacking for HCMV protease. Despite being a serine protease,
HCMV protease has many unique biochemical and structural features and belongs
to a new class of serine protease, distinct from the classical serine proteases
such as chymotrypsin and subtilisin. Therefore, a new body of knowledge is
needed on this new class of enzymes. The proposed research will use structural,
biochemical and biophysical techniques to achieve a greater understanding of
the molecular basis for the inhibition and the catalytic mechanism of HCMV
protease. Special emphasis will be placed on studying the unique features of
the protease, such as the Ser-His-His catalytic triad, the requirement for
dimerization for activity, the activation by antichaotropic agents, the
conformational flexibility and the induced fit behavior, and the inhibition of
the protease by non-peptidic and peptidomimetic compounds. The crystal
structure of HCMV protease free enzyme and the recently determined structure of
the protease inhibitor complex represent an excellent starting point for the
performance and completion of the proposed research. A long-term goal of the
research is to expand the studies to include the proteases of other
herpesviruses, many of which (herpes simplex virus and Kaposi's sarcoma
associated herpesvirus) are also targets for the development of anti-herpes
agents.
Status | Finished |
---|---|
Effective start/end date | 6/1/99 → 5/31/04 |
Funding
- National Institute of Allergy and Infectious Diseases: US$252,643.00
- National Institute of Allergy and Infectious Diseases: US$996,293.00
- National Institute of Allergy and Infectious Diseases: US$245,285.00
- National Institute of Allergy and Infectious Diseases: US$238,141.00
ASJC Scopus Subject Areas
- Infectious Diseases
- Virology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.